loading page

Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms
  • +19
  • Jean Bousquet,
  • Detlef Schroder-Bernhardi,
  • Claus Bachert,
  • G. Walter Canonica,
  • Victoria Cardona,
  • Elisio Costa,
  • Wienczyslawa Czarlewski,
  • Philippe Devillier,
  • João Fonseca,
  • Ludger Klimek,
  • Piotr Kuna ,
  • Olga Lourenço,
  • Joaquim Mullol,
  • Oliver Pfaar,
  • Nhan Pham Thi,
  • Bolesław Samoliński,
  • Julia Saueressig,
  • Glenis Scadding,
  • Ann-Kathrin Stroh,
  • Sophie Scheire,
  • Eric VAN GANSE,
  • Torsten Zuberbier
Jean Bousquet
Université Versailles, St-Quentin-en-Yvelines
Author Profile
Detlef Schroder-Bernhardi
IQVIA
Author Profile
Claus Bachert
Upper Airway Research Laboratory (URL),
Author Profile
G. Walter Canonica
Humanitas University
Author Profile
Victoria Cardona
Hospital Vall d'Hebron
Author Profile
Elisio Costa
UCIBIO, REQUINTE
Author Profile
Wienczyslawa Czarlewski
Medical Consulting
Author Profile
Philippe Devillier
Universite Versailles Saint-Quentin-en-Yvelines
Author Profile
João Fonseca
Hospital-CUF Porto and Instituto CUF-Diagnóstico e Tratamento
Author Profile
Ludger Klimek
Zentrum für Rhinologie und Allergologie
Author Profile
Piotr Kuna
University Clinical Hospital No 1 N Barlicki in Lodz
Author Profile
Olga Lourenço
University of Beira Interior
Author Profile
Joaquim Mullol
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Author Profile
Oliver Pfaar
University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.
Author Profile
Nhan Pham Thi
Institut Pasteur
Author Profile
Bolesław Samoliński
Medical Uniwersity of Warsaw
Author Profile
Julia Saueressig
IQVIA Commercial GmbH and Co OHG
Author Profile
Glenis Scadding
Royal National Throat, Nose and Ear Hospital
Author Profile
Ann-Kathrin Stroh
IQVIA Germany
Author Profile
Sophie Scheire
Ghent University
Author Profile
Eric VAN GANSE
Université Lyon 1-CHU Lyon
Author Profile
Torsten Zuberbier
Charité Universitätsmedizin Berlin
Author Profile

Abstract

Background: The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. Methods: We conducted a pharmaco-epidemiological database analysis to assess the medications that were prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS® - Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking - OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). The UK was excluded due to a lack of data. Results: Intra-nasal decongestants were excluded from the analyses because they are not prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intra-nasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%) whereas the Italian market is dominated by systemic anti-histamines (41.4%) followed by intra-nasal corticosteroids (30.1%). Results of other years were similar. Discussion: There are major differences between countries in terms of rhino-conjunctivitis medication usage.